OZEM vs WDNA: Holdings Overlap & Returns
Over the year to Nov 13, 2026, OZEM returned +0.7% to WDNA's +43.3%; 13% of their weight is in the same names.
- Return gap
- +42.6 pts1 year to Nov 13, 2026: WDNA ahead, total return
- Fee gap
- 0.14 ptsA year: OZEM 0.59%, WDNA 0.45%, per filings dated Apr 30, 2026 and Oct 28, 2026
- Overlap
- 13%Share of the two books held in common, holdings dated Nov 13, 2026 and Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
OZEM +0.7%, WDNA +43.3%: WDNA +42.6 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Fees over time
Hypothetical. $10,000 in OZEM for 10 years at 0.59% a year costs about $972 in fees and lost growth; WDNA at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
30% of OZEM's weight is in S&P 500 companies and 70% is outside the index. Holdings as of Nov 13, 2026.
26% of WDNA's weight is in S&P 500 companies and 74% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
WDNA costs 0.14 points a year less; their one-year returns differ by 42.6 points.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +0.7% | +43.3% |
|---|---|---|
| Below its all-time high | 15.1%, high on Jan 26, 2026 | 13.9%, high on Sep 2, 2021 |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.59% | 0.45% |
| Net assets, OZEM as of Nov 13, 2026 and WDNA as of Jun 30, 2026 | $57m | $2.7m |
| Holdings in common | 13% |
The numbers behind it
Net assets: $57m on Nov 13, 2026 for Roundhill GLP-1 & Weight Loss ETF, and $2.7m on Jun 30, 2026 for WisdomTree BioRevolution Fund.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 13, 2026.
What they share
By the books each fund has filed, OZEM and WDNA hold 13% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 13, 2026.
half
13% in common
Held in common
Show all 7 holdings
| Eli Lilly & Co | 20.30% | 4.08% |
| Structure Therapeutics Inc | 2.96% | 2.12% |
| AstraZeneca PLC | 3.22% | 1.83% |
| Amgen Inc | 2.99% | 1.54% |
| Gilead Sciences Inc | 1.39% | 1.51% |
| Pfizer Inc | 5.69% | 1.34% |
| Viking Therapeutics Inc | 3.94% | 0.93% |
Only in OZEM
Show all 8 holdings
| Novo Nordisk A/S | 10.86% |
| Hanmi Pharm Co Ltd | 6.97% |
| Chugai Pharmaceutical Co Ltd | 6.82% |
| Kailera Therapeutics Inc | 4.89% |
| CSPC Pharmaceutical Group Ltd | 4.56% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 4.16% |
| Hansoh Pharmaceutical Group Co Ltd | 3.77% |
| Ascletis Pharma Inc | 3.36% |
Only in WDNA
Show all 8 holdings
| TWIST BIOSCIENCE CORP | 5.95% |
| MODERNA INC | 4.14% |
| JOHNSON & JOHNSON | 2.97% |
| UNITED THERAPEUTICS CORP | 2.45% |
| NATERA INC | 2.32% |
| TEMPUS AI INC | 2.28% |
| IMMUNOME INC | 2.26% |
| STOKE THERAPEUTICS INC | 2.09% |
Side by side
Open the table
| Fund | Roundhill GLP-1 & Weight Loss ETF · Holds 21 stocks in healthcare innovation and GLP-1, 30% of its weight in S&P 500 companies | WisdomTree BioRevolution Fund · Holds 80 stocks in healthcare innovation and GLP-1, 26% of its weight in S&P 500 companies |
| Issuer | Roundhill | WisdomTree |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 30.4% | 25.9% |
| Active share vs the S&P 500 | 97.8% | 95.3% |
| In the Nasdaq-100 | 4.4% | 5.2% |
| Holdings | 21 | 80 |
| Top ten, share of the fund | 72.0% | 30.7% |
| Expense ratio | 0.59% | 0.45% |
| Fee for the differing part | 0.60% | 0.47% |
| Total return, 1 year | +0.7% | +43.3% |
| vs its benchmark | not measured | not measured |
| Below its high | −15.1% | −13.9% |
| Net assets, OZEM as of Nov 13, 2026 and WDNA as of Jun 30, 2026 | $57m | $2.7m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −4.9% | +6.8% |
|---|---|---|
| 6 months | +1.8% | +30.6% |
| 1 year | +0.7% | +43.3% |
| 3 years | – | +62.5% |
| Since launch (Not the same days: OZEM May 2024 · WDNA Jun 2021) | +25.6% | −3.7% |
– means no data for this window.
About OZEM
By weight, 30% of OZEM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 72% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +0.7% with distributions reinvested. It sits 15.1% below its all-time high of Jan 26, 2026.
About WDNA
By weight, 26% of WDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 31% of the fund across 80 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +43.3% with distributions reinvested. It sits 13.9% below its all-time high of Sep 2, 2021.
13% of the two portfolios are the same securities at the same weight.
Questions people ask
Do OZEM and WDNA hold the same stocks?
By their latest filings, 13% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, OZEM against WDNA, data as of Nov 13, 2026. https://etfiq.com/compare/themes/ozem-vs-wdna
ETFIQ. (Nov 13, 2026). OZEM against WDNA. Retrieved from https://etfiq.com/compare/themes/ozem-vs-wdna
[OZEM against WDNA (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/ozem-vs-wdna)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.